| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Arcutis Biotherapeutics, Inc. (ARQT) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 15 sells. ARQT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 717.2K | $19.44M | -4,375 | |
| Other | 150.2K | $4.07M | - | |
| Other | 126.2K | $3.42M | -1,230 | |
| Other | 119.3K | $3.23M | -955 | |
| CFO | 86.0K | $2.33M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Watanabe Todd65 | See Remarks | Sell | 4,375 | $26.12 | $114,261.00 | -0.6% | - | - | |
| Aug 3, 2026 | Burnett Patrick | See Remarks | Sell | 955 | $26.12 | $24,941.54 | -0.8% | - | - | |
| Aug 3, 2026 | Matsuda Masaru51 | See Remarks | Sell | 1,230 | $26.12 | $32,123.66 | -1.0% | - | - | |
| Jun 17, 2026 | Welgus Howard G.59 | Director | Sale+OE | 4,731 | $24.58 | $116,280.94 | -5.9% | - | - | |
| Jun 15, 2026 | Lin Sue-Jean | Director | Sell | 4,946 | $24.38 | $120,586.94 | -15.2% | - | - | |
| May 11, 2026 | Burnett Patrick | See Remarks | Sell | 222 | $21.05 | $4,673.10 | -0.2% | - | - | |
| May 11, 2026 | Vairavan Latha | SVP Chief Financial Officer | Sell | 435 | $21.05 | $9,156.75 | -0.5% | - | - | |
| May 4, 2026 | Matsuda Masaru51 | See Remarks | Sell | 8,256 | $23.31 | $192,415.26 | -3.1% | +14.3% | - | |
| Feb 2, 2026 | Matsuda Masaru51 | See Remarks | Sell | 40,638 | $25.28 | $1,027,292.65 | -7.5% | -8.7% | - | |
| Jan 5, 2026 | Burnett Patrick | See Remarks | Sell | 2,490 | $28.98 | $72,165.68 | -2.6% | -21.7% | - |